Fig. 1From: A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)Kaplan-Meier estimates of (a) the primary endpoint of progression free survival and (b) the secondary endpoint of overall survival (OS)Back to article page